Anti-EGFRvIII [L8A4] Antibody
This mouse IgG1 monoclonal antibody was generated against Pep 3, a 14-amino acid peptide corresponding to the predicted amino acid sequence at the fusion junction (LEEKKGNYVVTDHC), and is specific for human epidermal growth factor receptor variant III (EGFRvIII).
Highlights:
- Reacts with human EGFRvIII
- Suitable for Western Blot, Immunohistochemistry, ELISA and Flow Cytometry applications
Recombinant versions available from our sister company, Absolute Antibody:
- Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e., specificity) from the hybridoma L8A4.
The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas.
From the laboratory of Darell D. Bigner, MD, PhD, Duke University.
This mouse IgG1 monoclonal antibody was generated against Pep 3, a 14-amino acid peptide corresponding to the predicted amino acid sequence at the fusion junction (LEEKKGNYVVTDHC), and is specific for human epidermal growth factor receptor variant III (EGFRvIII).
Highlights:
- Reacts with human EGFRvIII
- Suitable for Western Blot, Immunohistochemistry, ELISA and Flow Cytometry applications
Recombinant versions available from our sister company, Absolute Antibody:
- Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e., specificity) from the hybridoma L8A4.
The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas.
From the laboratory of Darell D. Bigner, MD, PhD, Duke University.
| Catalog Number | Product | DataSheet | Size | AVAILABILITY | Price | Qty |
|---|
| Product Type: | Antibody |
| Name: | Anti-EGFRvIII [L8A4] |
| Antigen: | EGFRvIII |
| Accession ID: | P00533 |
| Molecular Weight: | 145 kDa |
| Isotype: |
EDK002: IgG1 Recombinant versions: see product name |
| Clonality: | Monoclonal |
| Clone Name: | L8A4 |
| Reactivity: | Human |
| Immunogen: | Pep 3, a 14-amino acid peptide corresponding to the predicted amino acid sequence at the fusion junction (LEEKKGNYVVTDHC), was synthesized, purified, and coupled to keyhole limpet hemocyanin |
| Species Immunized: | Mouse |
| Purification Method: | Protein G |
| Buffer: |
EDK002: PBS, 0.05% (w/v) Sodium Azide Recombinant versions: PBS with 0.02% Proclin 300 |
| Tested Applications: | WB (20 ug/mL), Immunohistochemistry, ELISA, flow cytometry |
| Storage: | -20C |
| Shipped: | Cold Packs |
- Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995 Jul 15;55(14):3140-8
If you publish research with this product, please let us know so we can cite your paper.
